|6th October 2020||John L Lamattina||46,388||Conversion of derivative||$0.00|
|26th June 2020||Thomas Edward Hamilton||159,433||Other acquisition or disposition||$0.00|
|26th June 2020||Carole Ben Maimon||25,083||Other acquisition or disposition||$0.00|
|26th June 2020||Thomas Edward Hamilton||133,420||Other acquisition or disposition||$0.00|
|26th June 2020||Therapeutics Holdings, Llc Chondrial||6,091,242||Other acquisition or disposition||$0.00|
|10th June 2020||John L Lamattina||831||Grant/award etc.||$0.00|
|15th May 2020||Thomas Edward Hamilton||200,000||Open or private purchase||$5.96||$1,192,920.00|
|17th December 2019||Robert J Perez||2,500||Disposition due to a tender of shares in a change of control transaction||$114.50||$286,250.00|
|1st August 2019||John L Lamattina||847||Payment by withholding||$95.58||$80,958.29|
|1st August 2019||John L Lamattina||2,500||Exercise of derivative||$32.30||$80,750.00|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 9/10.
Zafgen, Inc. is a biopharmaceutical company. It focuses on the study of MetAP2 inhibitors in both common and rare metabolic disorders. The firm also advancing programs for type 2 diabetes, Prader-Willi syndrome, and liver diseases.